Kane Biotech to Present at Advanced Wound Care Summit USA
Kane Biotech (TSX-V: KNE) has announced that Interim CEO Dr. Robert Huizinga will present at the 4th Advanced Wound Care Summit USA in Boston, MA from July 15-17, 2025. The summit brings together industry leaders, innovators, payers, and regulators in the wound care sector to discuss transforming breakthrough science into accessible therapies.
Dr. Huizinga's presentation will be made available on Kane's website on July 16, 2025.
Kane Biotech (TSX-V: KNE) ha annunciato che il CEO ad interim, il Dr. Robert Huizinga, presenterà al 4° Summit Avanzato sulla Cura delle Ferite USA a Boston, MA, dal 15 al 17 luglio 2025. Il summit riunisce leader del settore, innovatori, enti pagatori e regolatori nel campo della cura delle ferite per discutere di come trasformare le scoperte scientifiche rivoluzionarie in terapie accessibili.
La presentazione del Dr. Huizinga sarà disponibile sul sito web di Kane il 16 luglio 2025.
Kane Biotech (TSX-V: KNE) ha anunciado que el CEO interino, el Dr. Robert Huizinga, presentará en la 4ª Cumbre Avanzada de Cuidado de Heridas USA en Boston, MA, del 15 al 17 de julio de 2025. La cumbre reúne a líderes de la industria, innovadores, pagadores y reguladores del sector del cuidado de heridas para debatir sobre la transformación de avances científicos revolucionarios en terapias accesibles.
La presentación del Dr. Huizinga estará disponible en el sitio web de Kane el 16 de julio de 2025.
Kane Biotech (TSX-V: KNE)는 임시 CEO인 Dr. Robert Huizinga가 2025년 7월 15일부터 17일까지 매사추세츠주 보스턴에서 열리는 제4회 미국 첨단 상처 치료 정상회의에서 발표할 것이라고 발표했습니다. 이 정상회의는 상처 치료 분야의 업계 리더, 혁신가, 지불자 및 규제 기관을 한자리에 모아 획기적인 과학을 접근 가능한 치료법으로 전환하는 방안을 논의합니다.
Dr. Huizinga의 발표는 2025년 7월 16일 Kane 웹사이트에서 제공될 예정입니다.
Kane Biotech (TSX-V : KNE) a annoncé que le PDG par intérim, le Dr Robert Huizinga, présentera lors du 4e Sommet Avancé sur les Soins des Plaies aux États-Unis à Boston, MA, du 15 au 17 juillet 2025. Ce sommet réunit des leaders de l'industrie, des innovateurs, des payeurs et des régulateurs du secteur des soins des plaies pour discuter de la transformation des avancées scientifiques révolutionnaires en thérapies accessibles.
La présentation du Dr Huizinga sera disponible sur le site web de Kane le 16 juillet 2025.
Kane Biotech (TSX-V: KNE) hat bekanntgegeben, dass der interimistische CEO Dr. Robert Huizinga auf dem 4. Advanced Wound Care Summit USA in Boston, MA, vom 15. bis 17. Juli 2025 präsentieren wird. Der Gipfel bringt Branchenführer, Innovatoren, Kostenträger und Regulierungsbehörden im Bereich der Wundversorgung zusammen, um darüber zu diskutieren, wie bahnbrechende Wissenschaft in zugängliche Therapien umgesetzt werden kann.
Dr. Huizingas Präsentation wird am 16. Juli 2025 auf der Website von Kane verfügbar sein.
- None.
- None.
WINNIPEG, Manitoba, July 14, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane Biotech” or “Kane”) announces today that Kane Biotech’s Interim Chief Executive Officer, Dr. Robert Huizinga, will be presenting at the 4th Advanced Wound Care Summit USA taking place from July 15-17, 2025 in Boston, MA.
The Advanced Wound Care Summit USA is an industry gathering dedicated to the business of wound care where innovators, payers, regulators, and multinational leaders come together to turn breakthrough science into profitable, accessible therapies.
Dr. Huizinga’s presentation will be available on Kane’s website as of July 16, 2025.
About Kane Biotech
Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds which results in serious clinical outcomes and significant cost. revyve™ addresses both biofilms and wound bacteria.
For more information:
| Dr. Robert Huizinga | Ray Dupuis | ||||
| Interim CEO | Chief Financial Officer | ||||
| Kane Biotech Inc | Kane Biotech Inc | ||||
| rhuizinga@kanebiotech.com | rdupuis@kanebiotech.com | ||||
| (780) 970-1100 | (204) 298-2200 | ||||
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar+.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
FAQ
When is Kane Biotech (KNBIF) presenting at the Advanced Wound Care Summit 2025?
Where can I access Kane Biotech's Advanced Wound Care Summit 2025 presentation?
Who is presenting for Kane Biotech at the Advanced Wound Care Summit 2025?
What is the purpose of the Advanced Wound Care Summit USA 2025?
